Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02390427 |
|
Recruitment Status :
Active, not recruiting
First Posted : March 17, 2015
Last Update Posted : February 28, 2024
|
Sponsor:
Otto Metzger, MD
Collaborator:
Genentech, Inc.
Information provided by (Responsible Party):
Otto Metzger, MD, Dana-Farber Cancer Institute
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Actual Primary Completion Date : | December 2022 |
| Estimated Study Completion Date : | May 2024 |